Growth hormone does not prevent catabolic side effects of dexamethasone in extremely low birth weight preterm infants with bronchopulmonary dysplasia - A pilot study

Giorgio Tonini, Tamara Pahor, Franco Colonna, Umberto De Vonderweid

Research output: Contribution to journalArticle

Abstract

Recombinant human growth hormone (rhGH) may reduce the catabolic side effects of steroid therapies on children and adults, but this has never been studied in preterm infants. We performed a pilot study on 5 extremely low birth weight preterm infants (gestational age 27 ± 3 wks, birth weight 824 ± 160 g) still on mechanical ventilation for bronchopulmonary dysplasia at the postnatal age of 35 ± 3 days. All were treated for 7 days with dexamethasone (0.5 mg/kg/d iv) and subcutaneous rhGH at different doses: 0.1 (n=1), 0.2 (n=2) or 0.3 (n=2) IU/kg/day. Nutrition was kept stable. After 7 days all subjects improved their respiratory condition but body weight remained the same and urinary urea nitrogen and C-peptide were signicantly higher (p <0.001), rhGH intake strongly related to urinary excretion of urea nitrogen (r = 0.78) and C-peptide (r = 0.88). Dexamethasone improves the pulmonary function of very preterm infants with bronchopulmonary dysplasia but induces growth arrest and catabolism which are not prevented, and may be worsened, by rhGH.

Original languageEnglish
Pages (from-to)291-294
Number of pages4
JournalJournal of Pediatric Endocrinology and Metabolism
Volume10
Issue number3
Publication statusPublished - 1997

Keywords

  • Bronchopulmonary dysplasia
  • C-peptide
  • Dexamethasone
  • Growth hormone
  • Preterm newborn

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Growth hormone does not prevent catabolic side effects of dexamethasone in extremely low birth weight preterm infants with bronchopulmonary dysplasia - A pilot study'. Together they form a unique fingerprint.

Cite this